<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0">
    <channel>
        <title>American Heart Journal via MedWorm.com</title>
        <description>MedWorm.com provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest items from the 'American Heart Journal' source.</description>
        <link><![CDATA[http://www.medworm.com/rss/search.php?qu=American+Heart+Journal&t=American+Heart+Journal&s=Search&f=source]]></link>
        <lastBuildDate>Wed, 08 Feb 2012 09:32:26 +0100</lastBuildDate>
        <item>
            <title>Information for Readers</title>
            <link>http://www.medworm.com/index.php?rid=5659566&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS0002870312000154%2Fabstract%3Frss%3Dyes</link>
            <description>(Source: American Heart Journal)</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5659566</comments>
            <pubDate>Wed, 01 Feb 2012 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">5659566</guid>        </item>
        <item>
            <title>Editorial Board</title>
            <link>http://www.medworm.com/index.php?rid=5659565&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS0002870312000142%2Fabstract%3Frss%3Dyes</link>
            <description>(Source: American Heart Journal)</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5659565</comments>
            <pubDate>Wed, 01 Feb 2012 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">5659565</guid>        </item>
        <item>
            <title>Table of Contents</title>
            <link>http://www.medworm.com/index.php?rid=5659564&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS0002870312000130%2Fabstract%3Frss%3Dyes</link>
            <description>(Source: American Heart Journal)</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5659564</comments>
            <pubDate>Wed, 01 Feb 2012 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">5659564</guid>        </item>
        <item>
            <title>Obesity and physical fitness in California school children</title>
            <link>http://www.medworm.com/index.php?rid=5659563&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS0002870311008258%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusions: Following prevention measures within California public schools, obesity and fitness levels have stabilized. However, continued increases in early entrance (5th grade) obesity will require additional efforts directed at preschool and elementary students to completely stop and reverse this obesity epidemic. (Source: American Heart Journal)</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5659563</comments>
            <pubDate>Wed, 01 Feb 2012 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">5659563</guid>        </item>
        <item>
            <title>Aggregating traditional cardiovascular disease risk factors to assess the cardiometabolic health of childhood cancer survivors: An analysis from the Cardiac Risk Factors in Childhood Cancer Survivors Study</title>
            <link>http://www.medworm.com/index.php?rid=5659562&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS0002870311008234%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusions: Cardiometabolic health is poor in childhood cancer survivors but not different than that of their siblings, highlighting the importance of managing traditional CVD risk factors and considering novel exposures in survivors. (Source: American Heart Journal)</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5659562</comments>
            <pubDate>Wed, 01 Feb 2012 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">5659562</guid>        </item>
        <item>
            <title>Survival and predictive factors of mortality after 30 days in patients treated with percutaneous implantation of the CoreValve aortic prosthesis</title>
            <link>http://www.medworm.com/index.php?rid=5659561&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS0002870311008295%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusions: Transcatheter aortic valve implantation with the CoreValve prosthesis for patients with aortic stenosis and a high surgical risk is a safe, efficient option resulting in a medium-term clinical improvement. Survival during follow-up depends on the associated comorbidities. Early mortality beyond 30 days is predicted by preoperative comorbidity scores and the functional status of the patient. (Source: American Heart Journal)</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5659561</comments>
            <pubDate>Wed, 01 Feb 2012 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">5659561</guid>        </item>
        <item>
            <title>Cardiopulmonary exercise function among patients undergoing transcatheter pulmonary valve implantation in the US Melody valve investigational trial</title>
            <link>http://www.medworm.com/index.php?rid=5659560&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS0002870311007770%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusion: In patients with RV to pulmonary artery conduit dysfunction, TPV is associated with modest improvement in exercise capacity and gas exchange efficiency during exercise. (Source: American Heart Journal)</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5659560</comments>
            <pubDate>Wed, 01 Feb 2012 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">5659560</guid>        </item>
        <item>
            <title>Associations of pentraxin-3 with cardiovascular events, incident heart failure, and mortality among persons with coronary heart disease: Data from the Heart and Soul Study</title>
            <link>http://www.medworm.com/index.php?rid=5659559&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS0002870311008222%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusions: Among persons with stable CHD, higher PTX3 concentrations were associated with increased risk for all-cause mortality, CV events, and incident HF independently of systemic inflammation. Adjustment for eGFR modestly attenuated these associations, suggesting that future studies of PTX3 should adjust for kidney function. (Source: American Heart Journal)</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5659559</comments>
            <pubDate>Wed, 01 Feb 2012 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">5659559</guid>        </item>
        <item>
            <title>Frequency and impact of lifestyle modification in patients with coronary artery disease: The Japanese Coronary Artery Disease (JCAD) Study</title>
            <link>http://www.medworm.com/index.php?rid=5659558&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS0002870311007745%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusions: Exercise and diet interventions have a beneficial impact on all-cause mortality in patients with CAD, yet these interventions are surprisingly infrequent. Lifestyle interventions should be more actively promoted. (Source: American Heart Journal)</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5659558</comments>
            <pubDate>Wed, 01 Feb 2012 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">5659558</guid>        </item>
        <item>
            <title>Effect of QRS morphology on clinical event reduction with cardiac resynchronization therapy: Meta-analysis of randomized controlled trials</title>
            <link>http://www.medworm.com/index.php?rid=5659557&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS0002870311008301%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusions: While CRT was very effective in reducing clinical events in patients with LBBB, it did not reduce such events in patients with wide QRS due to other conduction abnormalities. (Source: American Heart Journal)</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5659557</comments>
            <pubDate>Wed, 01 Feb 2012 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">5659557</guid>        </item>
        <item>
            <title>Comparison of processes of care and clinical outcomes for patients newly hospitalized for heart failure attended by different physician specialists</title>
            <link>http://www.medworm.com/index.php?rid=5659556&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS0002870311008283%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusion: Physician specialty-related differences in HF outcomes appear to reflect a combination of both case-mix differences and differences in the use of certain heart failure processes of care. These findings suggest that it may be possible to improve HF outcomes in patients receiving care from generalist physicians. (Source: American Heart Journal)</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5659556</comments>
            <pubDate>Wed, 01 Feb 2012 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">5659556</guid>        </item>
        <item>
            <title>Perceived sexual difficulties and associated factors in patients with heart failure</title>
            <link>http://www.medworm.com/index.php?rid=5659555&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS000287031100771X%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusions: Perceived difficulties in sexual activity are common in patients with HF, particularly in younger and male patients and continue over time. Patients who perceive difficulties in sexual activity report a significant lower QoL and overall well-being than those who do not. (Source: American Heart Journal)</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5659555</comments>
            <pubDate>Wed, 01 Feb 2012 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">5659555</guid>        </item>
        <item>
            <title>Patient and hospital characteristics associated with traditional measures of inpatient quality of care for patients with heart failure</title>
            <link>http://www.medworm.com/index.php?rid=5659554&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS0002870311007228%2Fabstract%3Frss%3Dyes</link>
            <description>Background: The purpose of this study was to determine patient and hospital characteristics associated with 4 measures of quality of inpatient heart failure care used by both the primary payer of heart failure care in the United States (Center for Medicare and Medicaid Services) and the main hospital accrediting organization (The Joint Commission).Methods: We used data from Get With The Guidelines Program for patients hospitalized with heart failure. Eligibility for receiving care based on the Center for Medicare and Medicaid Services performance measures was determined for assessment of left ventricular ejection fraction (LVEF; n = 60,601), use of angiotensin-converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARB) if LVEF (Source: American Heart Journal)</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5659554</comments>
            <pubDate>Wed, 01 Feb 2012 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">5659554</guid>        </item>
        <item>
            <title>Percutaneous coronary intervention outcomes in US hospitals with varying structural characteristics: Analysis of the NCDR®</title>
            <link>http://www.medworm.com/index.php?rid=5659552&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS0002870311007708%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusions: Specialty hospitals appear to have lower rates of most adverse outcomes for PCI. Specialty hospitals may have developed expertise in narrow procedural areas that could be adapted to the larger population of general hospitals. (Source: American Heart Journal)</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5659552</comments>
            <pubDate>Wed, 01 Feb 2012 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">5659552</guid>        </item>
        <item>
            <title>Indications for percutaneous coronary interventions performed in US hospitals: a report from the NCDR®</title>
            <link>http://www.medworm.com/index.php?rid=5659551&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS0002870311007691%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusions: A small proportion of PCI procedures were performed in patients with unclear indications, but there was wide variation across hospitals. On average, specialty hospitals performed more PCIs for unclear indications. Efforts to reduce variability should be pursued. (Source: American Heart Journal)</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5659551</comments>
            <pubDate>Wed, 01 Feb 2012 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">5659551</guid>        </item>
        <item>
            <title>Circadian variations of ischemic burden among patients with myocardial infarction undergoing primary percutaneous coronary intervention</title>
            <link>http://www.medworm.com/index.php?rid=5659550&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS0002870311008210%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusion: This study demonstrates an independent correlation between the infarct size of STEMI patients treated by PPCI and the time of the day at which symptoms occurred. These results suggest that time of the day should be a critical issue to look at when assessing prognosis of patients with myocardial infarction. (Source: American Heart Journal)</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5659550</comments>
            <pubDate>Wed, 01 Feb 2012 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">5659550</guid>        </item>
        <item>
            <title>Single high-dose erythropoietin administration immediately after reperfusion in patients with ST-segment elevation myocardial infarction: results of the Erythropoietin in Myocardial Infarction Trial</title>
            <link>http://www.medworm.com/index.php?rid=5659549&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS0002870311008209%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusions: Single high-dose EPO administered immediately after successful reperfusion in patients with STEMI did not reduce infarct size at 3-month follow-up. However, this regimen decreased the incidence of MVO and was associated with transient favorable effects on LV volume and function. (Source: American Heart Journal)</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5659549</comments>
            <pubDate>Wed, 01 Feb 2012 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">5659549</guid>        </item>
        <item>
            <title>Statin treatment for coronary artery plaque composition based on intravascular ultrasound radiofrequency data analysis</title>
            <link>http://www.medworm.com/index.php?rid=5659548&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS0002870311008192%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusions: Both pitavastatin and pravastatin altered coronary artery plaque composition by significantly decreasing the fibrofatty plaque component and increasing the calcified plaque component. (Source: American Heart Journal)</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5659548</comments>
            <pubDate>Wed, 01 Feb 2012 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">5659548</guid>        </item>
        <item>
            <title>Reduced immediate ischemic events with cangrelor in PCI: A pooled analysis of the CHAMPION trials using the universal definition of myocardial infarction</title>
            <link>http://www.medworm.com/index.php?rid=5659547&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS0002870311007800%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusion: With the use of the universal definition of myocardial infarction, cangrelor was associated with a significant reduction in early ischemic events when compared with clopidogrel in patients with non–ST-elevation ACS undergoing PCI. (Source: American Heart Journal)</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5659547</comments>
            <pubDate>Wed, 01 Feb 2012 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">5659547</guid>        </item>
        <item>
            <title>Efficacy and safety of enoxaparin compared with unfractionated heparin in the pharmacoinvasive management of acute ST-segment elevation myocardial infarction: Insights from the TRANSFER-AMI trial</title>
            <link>http://www.medworm.com/index.php?rid=5659546&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS0002870311007757%2Fabstract%3Frss%3Dyes</link>
            <description>Aims: An early invasive strategy after fibrinolysis for ST-elevation myocardial infarction (STEMI) improves outcomes, but the relative efficacy and safety of enoxaparin compared with unfractionated heparin (UFH) as part of this approach are unknown.Methods and Results: In the TRANSFER-AMI trial, patients with high-risk STEMI received fibrinolysis and were then randomized to either standard treatment or to immediate transfer for coronary angiography. In this substudy, the outcome of patients aged (Source: American Heart Journal)</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5659546</comments>
            <pubDate>Wed, 01 Feb 2012 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">5659546</guid>        </item>
        <item>
            <title>Detection of periodontal bacteria in thrombi of patients with acute myocardial infarction by polymerase chain reaction</title>
            <link>http://www.medworm.com/index.php?rid=5659544&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS0002870311007721%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusions: Three species of periodontal bacteria were detected in the thrombi of patients with acute myocardial infarction. This raises the possibility that such bacteria are latently present in plaque and also suggests that these bacteria might have a role in plaque inflammation and instability. (Source: American Heart Journal)</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5659544</comments>
            <pubDate>Wed, 01 Feb 2012 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">5659544</guid>        </item>
        <item>
            <title>Management of cardiac toxicity in patients receiving vascular endothelial growth factor signaling pathway inhibitors</title>
            <link>http://www.medworm.com/index.php?rid=5659543&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS0002870311007782%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusions: The panel recommends that physicians (1) conduct and document a formal risk assessment for existing cardiovascular disease and potential cardiovascular complications before VSP inhibitor treatment recognizing that preexisting hypertension and cardiovascular disease are common in patients with cancer, (2) actively monitor for blood pressure elevations and cardiac toxicity with more frequent assessments during the first treatment cycle, and (3) aggressively manage blood pressure elevations and early symptoms and signs of cardiac toxicity to prevent clinically limiting complications of VSP inhibitor therapy. (Source: American Heart Journal)</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5659543</comments>
            <pubDate>Wed, 01 Feb 2012 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">5659543</guid>        </item>
        <item>
            <title>Design of the RELAXin in Acute Heart Failure Study</title>
            <link>http://www.medworm.com/index.php?rid=5659542&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS0002870311007241%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusions: Pre-RELAX-AHF results suggested that infusion of RLX030 may accelerate dyspnea relief and improve prognosis in patients hospitalized with AHF. RELAX-AHF-1 will further evaluate these effects. (Source: American Heart Journal)</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5659542</comments>
            <pubDate>Wed, 01 Feb 2012 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">5659542</guid>        </item>
        <item>
            <title>Rationale and design of the TAXUS Libertē Post-Approval Study: Examination of patients receiving the TAXUS Liberté stent with concomitant prasugrel therapy in routine interventional cardiology practice</title>
            <link>http://www.medworm.com/index.php?rid=5659541&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS0002870311007812%2Fabstract%3Frss%3Dyes</link>
            <description>Background: Observational studies of new coronary stents are necessary to assess performance in a variety of complex patient and lesion types. Furthermore, the optimal dose and duration of thienopyridine treatment is unclear, particularly in patients with complex clinical conditions. The TAXUS Libertē Post-Approval Study is designed to provide 5-year data on the TAXUS Liberté paclitaxel-eluting stent with concomitant prasugrel therapy in routine clinical practice and to contribute data to the DAPT study.Study Design: The TAXUS Libertē Post-Approval Study is a prospective, multicenter, observational study. Enrollment of approximately 4,200 patients receiving ≥1 TAXUS Liberté stents is planned. All patients without a contraindication will be prescribed prasugrel plus aspirin for 1 year...</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5659541</comments>
            <pubDate>Wed, 01 Feb 2012 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">5659541</guid>        </item>
        <item>
            <title>Newest-generation drug-eluting and bare-metal stents combined with prasugrel-based antiplatelet therapy in large coronary arteries: The BAsel Stent Kosten Effektivitäts Trial PROspective Validation Examination part II (BASKET-PROVE II) trial design</title>
            <link>http://www.medworm.com/index.php?rid=5659540&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS0002870311007083%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusions: This study will test the comparative long-term safety and efficacy of newest-generation stents on the background of contemporary antiplatelet therapy in a large all-comer population undergoing large native coronary artery stenting. (Source: American Heart Journal)</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5659540</comments>
            <pubDate>Wed, 01 Feb 2012 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">5659540</guid>        </item>
        <item>
            <title>A case where the principle of “one question, one answer” may work better</title>
            <link>http://www.medworm.com/index.php?rid=5659539&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS0002870311007095%2Fabstract%3Frss%3Dyes</link>
            <description>In the last decade, investigations on the use of drug-eluting stents (DES) for the treatment of coronary artery disease have generated 2 types of reaction: immense enthusiasm promoted by the ability of DES to substantially reduce the risk of restenosis compared with bare-metal stents (BMS) and a lot of caution caused by concern regarding an increased risk for late stent thrombosis with DES. The investigators of The BAsel Stent Kosten Effektivitäts Trial PROspective Validation Examination part II (BASKET-PROVE II) trial, the design of which is published in this issue of the journal, are to be commended for their significant contribution to both of these reactions. In the BASKET-LATE study, they reported an excess risk of thrombotic events after discontinuation of clopidogrel in the DES gro...</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5659539</comments>
            <pubDate>Wed, 01 Feb 2012 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">5659539</guid>        </item>
        <item>
            <title>Vascular complications and access crossover in 10,676 transradial percutaneous coronary procedures</title>
            <link>http://www.medworm.com/index.php?rid=5659553&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS0002870311007794%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusions: The present study, conducted in a center with high volume of radial procedures, shows that transradial approach is associated with a very low rate of VC, which is stable over time. On the contrary, access crossover rate decreased over time and differed according to operator (radial) experience. (Source: American Heart Journal)</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5659553</comments>
            <pubDate>Mon, 16 Jan 2012 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">5659553</guid>        </item>
        <item>
            <title>High-concentration versus titrated oxygen therapy in ST-elevation myocardial infarction: A pilot randomized controlled trial</title>
            <link>http://www.medworm.com/index.php?rid=5659545&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS0002870311007733%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusion: This study found no evidence of benefit or harm from high-concentration compared with titrated oxygen in initially uncomplicated STEMI. However, our estimates have wide CIs, and as a result, large randomized controlled trials are required to resolve the clinical uncertainty. (Source: American Heart Journal)</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5659545</comments>
            <pubDate>Mon, 16 Jan 2012 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">5659545</guid>        </item>
        <item>
            <title>Information for Readers</title>
            <link>http://www.medworm.com/index.php?rid=5504613&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS0002870311008350%2Fabstract%3Frss%3Dyes</link>
            <description>(Source: American Heart Journal)</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5504613</comments>
            <pubDate>Fri, 16 Dec 2011 02:35:17 +0100</pubDate>
            <guid isPermaLink="false">5504613</guid>        </item>
        <item>
            <title>Editorial Board</title>
            <link>http://www.medworm.com/index.php?rid=5504612&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS0002870311008349%2Fabstract%3Frss%3Dyes</link>
            <description>(Source: American Heart Journal)</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5504612</comments>
            <pubDate>Fri, 16 Dec 2011 02:35:17 +0100</pubDate>
            <guid isPermaLink="false">5504612</guid>        </item>
        <item>
            <title>Table of Contents</title>
            <link>http://www.medworm.com/index.php?rid=5504611&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS0002870311008337%2Fabstract%3Frss%3Dyes</link>
            <description>(Source: American Heart Journal)</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5504611</comments>
            <pubDate>Fri, 16 Dec 2011 02:35:17 +0100</pubDate>
            <guid isPermaLink="false">5504611</guid>        </item>
        <item>
            <title>Characteristics of sudden arrhythmic death in a diverse, urban community</title>
            <link>http://www.medworm.com/index.php?rid=5504608&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS0002870311007010%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusions: In a diverse, urban population, SAD incidence varied substantially by gender and race. Significant CAD accounted for far fewer SADs than previous studies but remained associated with a 2.6-fold higher risk as compared with control deaths. These findings may reflect the evolving contemporary epidemiology of SCD. (Source: American Heart Journal)</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5504608</comments>
            <pubDate>Fri, 16 Dec 2011 02:35:17 +0100</pubDate>
            <guid isPermaLink="false">5504608</guid>        </item>
        <item>
            <title>Sex-specific benefits of sirolimus-eluting stent on long-term outcomes in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: Insights from the Multicenter Evaluation of Single High-Dose Bolus Tirofiban Versus Abciximab With Sirolimus-Eluting Stent or Bare-Metal Stent in Acute Myocardial Infarction Study trial</title>
            <link>http://www.medworm.com/index.php?rid=5504605&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS0002870311007125%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusions: In this analysis, the clinical benefit of SES use, over BMS, at 3-year follow-up was restricted to men and was not observed among women. (Source: American Heart Journal)</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5504605</comments>
            <pubDate>Fri, 16 Dec 2011 02:35:17 +0100</pubDate>
            <guid isPermaLink="false">5504605</guid>        </item>
        <item>
            <title>Relationships between changes in patient-reported health status and functional capacity in outpatients with heart failure</title>
            <link>http://www.medworm.com/index.php?rid=5504603&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS0002870311007137%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusions: Changes in patient-reported health status are not highly correlated with changes in functional capacity. Our findings generally support the current practice of considering a 5-point change in the KCCQ within individuals to be clinically meaningful. (Source: American Heart Journal)</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5504603</comments>
            <pubDate>Fri, 16 Dec 2011 02:35:17 +0100</pubDate>
            <guid isPermaLink="false">5504603</guid>        </item>
        <item>
            <title>Diagnostic accuracy of a point-of-care troponin I assay for acute myocardial infarction within 3 hours after presentation in early presenters to the emergency department with chest pain</title>
            <link>http://www.medworm.com/index.php?rid=5504601&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS0002870311007216%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusion: In suspected patients with acute coronary syndrome presenting to the emergency department within 8 hours of symptom onset, 3 hours of serial testing with the Cardio3 TnI POC platform provides similar diagnostic accuracy for AMI as longer periods. (Source: American Heart Journal)</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5504601</comments>
            <pubDate>Fri, 16 Dec 2011 02:35:17 +0100</pubDate>
            <guid isPermaLink="false">5504601</guid>        </item>
        <item>
            <title>Bridging the gender gap: Insights from a contemporary analysis of sex-related differences in the treatment and outcomes of patients with acute coronary syndromes</title>
            <link>http://www.medworm.com/index.php?rid=5504600&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS0002870311007113%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusions: Despite temporal increases in the use of invasive cardiac procedures, women with ACS are still more likely to be treated conservatively, which may be due to underestimation of patient risk. Furthermore, they have worse in-hospital outcomes. Greater awareness of this paradox may assist in bridging the gap between current guidelines and management practices. (Source: American Heart Journal)</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5504600</comments>
            <pubDate>Fri, 16 Dec 2011 02:35:17 +0100</pubDate>
            <guid isPermaLink="false">5504600</guid>        </item>
        <item>
            <title>Factors associated with improvement in ejection fraction in clinical practice among patients with heart failure: Findings from IMPROVE HF</title>
            <link>http://www.medworm.com/index.php?rid=5504598&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS0002870311007149%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusions: Among patients with HF receiving care in cardiology/multispecialty practices participating in a performance measure intervention, surviving, and having repeat LVEF assessment, close to one third of patients had a &gt;10% improvement in LVEF at 24 months. These findings indicate that HF is not always a progressive disease and that differentiation of the heterogeneous HF phenotypes may set the stage for future research and therapeutic targets. (Source: American Heart Journal)</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5504598</comments>
            <pubDate>Fri, 16 Dec 2011 02:35:17 +0100</pubDate>
            <guid isPermaLink="false">5504598</guid>        </item>
        <item>
            <title>Eliminating untimely deaths of women from heart disease: Highlights from the Minnesota Women's Heart Summit</title>
            <link>http://www.medworm.com/index.php?rid=5504597&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS0002870311007058%2Fabstract%3Frss%3Dyes</link>
            <description>This report summarizes strategies identified during the conference to serve as springboards for more substantive future initiatives. These include, for example, standardized data collection and use of existing data sets to inform perspectives on sex-related cardiovascular issues, mandatory reporting of sex-specific data, and increased attention to underserved/high-risk women. Participants acknowledged that implementing these ideas would be challenging and recommended key priorities/next action steps such as providing services close to “point-of-life” rather than “point-of-care” and creation of policies and regulations so that resources and environmental modifications encouraging healthier lifestyle choices are promoted. Additional research is needed to improve identification, treat...</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5504597</comments>
            <pubDate>Fri, 16 Dec 2011 02:35:17 +0100</pubDate>
            <guid isPermaLink="false">5504597</guid>        </item>
        <item>
            <title>Single-bolus tenecteplase plus heparin compared with heparin alone for normotensive patients with acute pulmonary embolism who have evidence of right ventricular dysfunction and myocardial injury: Rationale and design of the Pulmonary Embolism Thrombolysis (PEITHO) trial</title>
            <link>http://www.medworm.com/index.php?rid=5504596&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS0002870311007162%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusions: By determining the benefits vs risks of thrombolysis in submassive or intermediate-risk PE, this trial is expected to answer a long-standing query on the management of this patient population. (Source: American Heart Journal)</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5504596</comments>
            <pubDate>Fri, 16 Dec 2011 02:35:17 +0100</pubDate>
            <guid isPermaLink="false">5504596</guid>        </item>
        <item>
            <title>Design of the Trial to Assess Chelation Therapy (TACT)</title>
            <link>http://www.medworm.com/index.php?rid=5504592&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS0002870311007150%2Fabstract%3Frss%3Dyes</link>
            <description>TACT is an National Institutes of Health–sponsored, randomized, double-blind, placebo-controlled, 2 × 2 factorial clinical trial testing the benefits and risks of 40 infusions of a multicomponent disodium EDTA chelation solution compared with placebo and of an oral, high-dose multivitamin and mineral supplement. TACT has randomized and will follow up 1,708 patients for an average of approximately 4 years. The primary end point is a composite of all-cause mortality, myocardial infarction, stroke, coronary revascularization, and hospitalization for angina. A 900-patient substudy will examine quality-of-life outcomes. The trial is designed to have &gt;85% power to detect a 25% relative reduction in the primary end point for each treatment factor. Enrollment began in September 2003 and was com...</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5504592</comments>
            <pubDate>Fri, 16 Dec 2011 02:35:17 +0100</pubDate>
            <guid isPermaLink="false">5504592</guid>        </item>
        <item>
            <title>Rationale and design of The Coronary Artery Bypass Grafting Surgery Off or On Pump Revascularization Study: A large international randomized trial in cardiac surgery</title>
            <link>http://www.medworm.com/index.php?rid=5504591&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS0002870311007204%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusions: CORONARY is the largest trial yet conducted comparing off-pump CABG to on-pump CABG. Its results will lead to a better understanding of the safety and efficacy of off-pump CABG. (Source: American Heart Journal)</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5504591</comments>
            <pubDate>Fri, 16 Dec 2011 02:35:17 +0100</pubDate>
            <guid isPermaLink="false">5504591</guid>        </item>
        <item>
            <title>Information for Readers</title>
            <link>http://www.medworm.com/index.php?rid=5468640&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS0002870311007861%2Fabstract%3Frss%3Dyes</link>
            <description>(Source: American Heart Journal)</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5468640</comments>
            <pubDate>Thu, 01 Dec 2011 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">5468640</guid>        </item>
        <item>
            <title>Editorial Board</title>
            <link>http://www.medworm.com/index.php?rid=5468639&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS000287031100785X%2Fabstract%3Frss%3Dyes</link>
            <description>(Source: American Heart Journal)</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5468639</comments>
            <pubDate>Thu, 01 Dec 2011 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">5468639</guid>        </item>
        <item>
            <title>Toc</title>
            <link>http://www.medworm.com/index.php?rid=5468638&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS0002870311007848%2Fabstract%3Frss%3Dyes</link>
            <description>(Source: American Heart Journal)</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5468638</comments>
            <pubDate>Thu, 01 Dec 2011 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">5468638</guid>        </item>
        <item>
            <title>A trial-based economic evaluation of 2 nurse-led disease management programs in heart failure</title>
            <link>http://www.medworm.com/index.php?rid=5468637&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS0002870311007046%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusions: Although the differences in costs and effects among the 3 study groups were not statistically significant, from a decision-making perspective, basic support still had a relatively large probability of generating the highest health outcomes at the lowest costs. Our results also substantiated that a stratified approach based on offering basic support to patients with mild to moderate HF and intensive support to patients with severe HF could further improve health outcomes at slightly higher costs. (Source: American Heart Journal)</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5468637</comments>
            <pubDate>Thu, 01 Dec 2011 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">5468637</guid>        </item>
        <item>
            <title>A randomized study of the effects of exercise training on patients with atrial fibrillation</title>
            <link>http://www.medworm.com/index.php?rid=5468635&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS0002870311006983%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusion: Twelve weeks of exercise training increased exercise capacity and 6MWT and decreased resting pulse rate significantly in patients with AF. Overall quality of life increased significantly as measured by the cardiology-related MLHF-Q. Cardiac output and natriuretic peptides were unchanged in both groups. (Source: American Heart Journal)</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5468635</comments>
            <pubDate>Thu, 01 Dec 2011 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">5468635</guid>        </item>
        <item>
            <title>Trends and predictors of length of stay after primary percutaneous coronary intervention: A report from the CathPCI Registry</title>
            <link>http://www.medworm.com/index.php?rid=5468632&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS0002870311006909%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusions: While the predicted risk profile has remained stable, there has been a significant decrease in LOS after PPCI. Nevertheless, hospitals vary in discharging low-risk and uncomplicated patients early. Discharge within 2 days was associated with specific patient, procedure, and hospital factors. Further study is needed to determine the safety of early discharge among patients undergoing PPCI. (Source: American Heart Journal)</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5468632</comments>
            <pubDate>Thu, 01 Dec 2011 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">5468632</guid>        </item>
        <item>
            <title>Is cardiac catheterization necessary before initial management of patients with stable ischemic heart disease? Results from a Web-based survey of cardiologists</title>
            <link>http://www.medworm.com/index.php?rid=5468630&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS0002870311006417%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusions: Most surveyed cardiologists were willing to enroll SIHD patients with at least moderate ischemia into a trial with an initial noninvasive strategy arm. These findings support the feasibility of planning a large-scale trial to test the role of cardiac catheterization and revascularization in the initial management of SIHD patients with moderate or severe ischemia. (Source: American Heart Journal)</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5468630</comments>
            <pubDate>Thu, 01 Dec 2011 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">5468630</guid>        </item>
        <item>
            <title>Effects of atorvastatin pretreatment on infarct size in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention</title>
            <link>http://www.medworm.com/index.php?rid=5468629&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS0002870311006284%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusions: Pretreatment with high-dose atorvastatin followed by further treatment for 5 days did not reduce infarct size measured by single-photon emission computed tomography in patients undergoing primary PCI. (Source: American Heart Journal)</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5468629</comments>
            <pubDate>Thu, 01 Dec 2011 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">5468629</guid>        </item>
        <item>
            <title>Benefit of exercise therapy for systolic heart failure in relation to disease severity and etiology—findings from the Heart Failure and A Controlled Trial Investigating Outcomes of Exercise Training study</title>
            <link>http://www.medworm.com/index.php?rid=5468626&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS0002870311007022%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusion: Consideration of symptomatic (New York Heart Association classes II to IV) patients with HF with reduced LV function for participation in an exercise training program should be made independent of the cause of HF or the severity of the symptoms. (Source: American Heart Journal)</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5468626</comments>
            <pubDate>Thu, 01 Dec 2011 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">5468626</guid>        </item>
        <item>
            <title>Developing mechanistic insights into cardiovascular cell therapy: Cardiovascular Cell Therapy Research Network Biorepository Core Laboratory rationale</title>
            <link>http://www.medworm.com/index.php?rid=5468622&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS0002870311004182%2Fabstract%3Frss%3Dyes</link>
            <description>Moderate improvements in cardiac performance have been reported in some clinical settings after delivery of bone marrow mononuclear cells to patients with cardiovascular disease. However, mechanistic insights into how these cells impact outcomes are lacking. To address this, the National Heart, Lung and Blood Institute (NHLBI) Cardiovascular Cell Therapy Research Network (CCTRN) established a Biorepository Core for extensive phenotyping and cell function studies and storing bone marrow and peripheral blood for 10 years. Analyzing cell populations and cell function in the context of clinical parameters and clinical outcomes after cell or placebo treatment empower the development of novel diagnostic and prognostics. Developing such biomarkers that define the safety and efficacy of cell thera...</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5468622</comments>
            <pubDate>Thu, 01 Dec 2011 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">5468622</guid>        </item>
        <item>
            <title>A proinflammatory monocyte response is associated with myocardial injury and impaired functional outcome in patients with ST-segment elevation myocardial infarction: Monocytes and myocardial infarction</title>
            <link>http://www.medworm.com/index.php?rid=5504599&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS0002870311006429%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusions: This study shows an association between a proinflammatory monocyte response, characterized by high levels of classical monocytes, and severe myocardial injury and poor functional outcome after STEMI. Future studies are required to investigate the biologic nature of this association and therapeutic implications. (Source: American Heart Journal)</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5504599</comments>
            <pubDate>Thu, 24 Nov 2011 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">5504599</guid>        </item>
        <item>
            <title>Reply to the letter by Chatterjee et al “Bleeding, mortality, and antiplatelet therapy: Results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial”</title>
            <link>http://www.medworm.com/index.php?rid=5504610&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS0002870311007186%2Fabstract%3Frss%3Dyes</link>
            <description>In response to the questions from Chatterjee et al, we had already evaluated the association between Global Use of Strategies to Open Occluded Coronary Arteries bleeding—severe, moderate, and combined moderate or severe—and mortality. The association between bleeding and mortality was present, whichever definition of bleeding was used. Patients with fatal hemorrhage and intracranial bleeds were excluded from the bleeding analysis because these events are highly correlated with death and, thus, would overestimate the relationship between bleeding and death. Thus, the exclusion of these subjects makes our observations more conservative. (Source: American Heart Journal)</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5504610</comments>
            <pubDate>Wed, 23 Nov 2011 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">5504610</guid>        </item>
        <item>
            <title>Bleeding, mortality, and antiplatelet therapy: Results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial</title>
            <link>http://www.medworm.com/index.php?rid=5504609&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS0002870311007174%2Fabstract%3Frss%3Dyes</link>
            <description>We read with great interest the article by Berger et al regarding bleeding and its effects on all-cause, cardiovascular, and cancer mortality in stable patients and its relation with antiplatelet use. (Source: American Heart Journal)</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5504609</comments>
            <pubDate>Wed, 23 Nov 2011 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">5504609</guid>        </item>
        <item>
            <title>Nonfatal myocardial infarction and long-term outcomes in coronary artery disease</title>
            <link>http://www.medworm.com/index.php?rid=5504604&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS0002870311007101%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusions: Nonfatal MIs occurring within the first 3 and 6 months after diagnostic catheterization are associated with a significant increase in the risk for subsequent clinical events. Clinical studies with limited follow-up periods may underestimate the long-term value of therapies that reduce early MI rates as downstream benefits continue to accrue over time. (Source: American Heart Journal)</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5504604</comments>
            <pubDate>Wed, 23 Nov 2011 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">5504604</guid>        </item>
        <item>
            <title>A cardiovascular safety study of LibiGel (testosterone gel) in postmenopausal women with elevated cardiovascular risk and hypoactive sexual desire disorder</title>
            <link>http://www.medworm.com/index.php?rid=5504595&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS000287031100706X%2Fabstract%3Frss%3Dyes</link>
            <description>Evaluation of the safety of hormonal preparations for the treatment of female sexual dysfunction is important to assess the benefit-to-risk profile of these drugs and has been strongly encouraged by the Food and Drug Administration. LibiGel (Biosante Pharmaceuticals, Inc., Lincolnshire, IL), a low-dose testosterone gel, is under development for the treatment of hypoactive sexual desire disorder (HSDD) in oophorectomized women. To evaluate the long-term effects of LibiGel on risk for cardiovascular (CV) events, breast cancer, and general safety, a randomized, placebo-controlled clinical study using a novel adaptive design to optimize sample size and power is being conducted. The primary end point of the BioSante LibiGel Safety Study (BLISS) is a composite of CV events including death, nonfa...</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5504595</comments>
            <pubDate>Wed, 23 Nov 2011 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">5504595</guid>        </item>
        <item>
            <title>The role of transthoracic echocardiography in the diagnosis and management of acute type A aortic syndrome</title>
            <link>http://www.medworm.com/index.php?rid=5504606&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS0002870311007071%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusions: Transthoracic echocardiography is a useful imaging modality for the diagnosis of classic acute type A aortic dissection. It cannot be used as the sole screening technique for detecting AAAS, but in the light of the predictive values observed, patients with optimal image quality and clear-cut diagnosis of AAAS should proceed to the operative room, whereas in patients with negative or indeterminate studies, other imaging techniques are needed to refine the diagnosis. (Source: American Heart Journal)</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5504606</comments>
            <pubDate>Mon, 21 Nov 2011 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">5504606</guid>        </item>
        <item>
            <title>International longitudinal registry of patients with atrial fibrillation at risk of stroke: Global Anticoagulant Registry in the FIELD (GARFIELD)</title>
            <link>http://www.medworm.com/index.php?rid=5504593&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS000287031100696X%2Fabstract%3Frss%3Dyes</link>
            <description>Background: Atrial fibrillation (AF) is associated with high rates of morbidity and mortality. Patients with AF carry a fivefold increased risk of stroke and the risk of death from AF-related stroke is doubled. Current management is often inadequate, leaving patients at risk for a potentially fatal or disabling event. The purpose of the GARFIELD registry is to evaluate the management and outcomes of patients with newly diagnosed non-valvular AF at risk for stroke.Design: The GARFIELD registry is an observational, multicenter, prospective study of patients with newly diagnosed AF and one or more additional risk factors for stroke. The aim is to enroll 55,000 patients at &gt;1,000 centers in 50 countries. Enrollment will take place in five independent, sequential, prospective cohorts. An additi...</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5504593</comments>
            <pubDate>Mon, 21 Nov 2011 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">5504593</guid>        </item>
        <item>
            <title>Plasma resistin, adiponectin, and risk of incident atrial fibrillation: The Framingham Offspring Study</title>
            <link>http://www.medworm.com/index.php?rid=5504607&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS000287031100723X%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusion: In our community-based longitudinal study, higher mean concentrations of resistin were associated with incident AF, but the relation was attenuated by adjustment for C-reactive protein. We did not detect a statistically significant association between adiponectin and incident AF. Additional studies are needed to clarify the potential role of adipokines in AF and mechanisms linking adiposity to AF. (Source: American Heart Journal)</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5504607</comments>
            <pubDate>Fri, 18 Nov 2011 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">5504607</guid>        </item>
        <item>
            <title>Long-term effects of smoking and smoking cessation on exercise stress testing: Three-year outcomes from a randomized clinical trial</title>
            <link>http://www.medworm.com/index.php?rid=5504602&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS0002870311004935%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusions: Smokers with a higher smoking burden have lower exercise capacity, lower HR reserve, and a blunted exercise HR response. After 3 years, TST improvements suggestive of improved CVD prognosis were observed among successful abstainers. (Source: American Heart Journal)</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5504602</comments>
            <pubDate>Wed, 16 Nov 2011 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">5504602</guid>        </item>
        <item>
            <title>Responses of mental stress–induced myocardial ischemia to escitalopram treatment: Background, design, and method for the Responses of Mental Stress Induced Myocardial Ischemia to Escitalopram Treatment trial</title>
            <link>http://www.medworm.com/index.php?rid=5504594&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS0002870311007034%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusion: The REMIT study examines the effect of SSRI on MSIMI in vulnerable patients with CHD and probes some potential underlying mechanisms. (Source: American Heart Journal)</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5504594</comments>
            <pubDate>Wed, 16 Nov 2011 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">5504594</guid>        </item>
        <item>
            <title>Risk of target lesion failure in relationship to vessel angiographic geometry and stent conformability using the second generation of drug-eluting stents</title>
            <link>http://www.medworm.com/index.php?rid=5468634&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS0002870311006958%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusions: Bended, curved, and angulated lesions and changes in the number of bends/lesion, vessel curvature, and angulation from pre to post-implantation have no relation with TLF and TLR at 1 year and have no relation with In-hospital AMI using second-generation of DES. Resolute appears to be more conformable than Xience. (Source: American Heart Journal)</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5468634</comments>
            <pubDate>Thu, 10 Nov 2011 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">5468634</guid>        </item>
        <item>
            <title>Temporal trends in gastrointestinal bleeding associated with percutaneous coronary intervention: Analysis of the 1998-2006 Nationwide Inpatient Sample (NIS) database</title>
            <link>http://www.medworm.com/index.php?rid=5468633&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS0002870311006910%2Fabstract%3Frss%3Dyes</link>
            <description>Background: Gastrointestinal bleeding (GIB) after percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS) and coronary artery disease (CAD) is associated with high morbidity and mortality.Methods: The NIS database from 1998 to 2006 was used to identify 1,216,759 PCIs performed for ACS and CAD. We sought to analyze temporal trends in the incidence and in-hospital outcomes of GIB associated with PCI along with its predictors.Results: The overall incidence of GIB was 1.04% (95% confidence interval (CI), 1.02%-1.06%). The incidence of GIB decreased over the study period (P for trend (Source: American Heart Journal)</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5468633</comments>
            <pubDate>Thu, 10 Nov 2011 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">5468633</guid>        </item>
        <item>
            <title>Platelet reactivity in patients with chronic kidney disease receiving adjunctive cilostazol compared with a high-maintenance dose of clopidogrel: Results of the Effect of Platelet Inhibition According to Clopidogrel Dose in Patients with Chronic Kidney Disease (PIANO-2 CKD) randomized study</title>
            <link>http://www.medworm.com/index.php?rid=5468628&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS0002870311006430%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusions: Adjunctive cilostazol improves platelet inhibition compared with 75 or 150 mg of clopidogrel in CKD patients undergoing hemodialysis. (Source: American Heart Journal)</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5468628</comments>
            <pubDate>Thu, 10 Nov 2011 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">5468628</guid>        </item>
        <item>
            <title>Treadmill testing improves survival prediction models in pulmonary arterial hypertension</title>
            <link>http://www.medworm.com/index.php?rid=5468627&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS0002870311007009%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusion: The study findings suggest that the addition of ETT parameters to the REVEAL prognostic equation improves the predictive value of the equation when 6-minute walk distance is unavailable. (Source: American Heart Journal)</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5468627</comments>
            <pubDate>Thu, 10 Nov 2011 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">5468627</guid>        </item>
        <item>
            <title>The Kinetics of Integrilin Limited by Obesity: A multicenter randomized pharmacokinetic and pharmacodynamic clinical trial</title>
            <link>http://www.medworm.com/index.php?rid=5468625&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS0002870311006995%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusions: Actual body weight eptifibatide dosing leads to higher plasma concentrations and greater platelet inhibition than standard or IBW dosing in obese patients undergoing PCI. Current recommendations for eptifibatide dosing may be inadequate in patients &gt;121 kg. Further study is warranted to define the optimal dosing of eptifibatide and other medications in obese patients. (Source: American Heart Journal)</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5468625</comments>
            <pubDate>Thu, 10 Nov 2011 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">5468625</guid>        </item>
        <item>
            <title>Mutations in the human phospholamban gene in patients with heart failure</title>
            <link>http://www.medworm.com/index.php?rid=5468636&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS0002870311006211%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusions: Mutations in the PLN gene are a rare cause of heart failure, present almost exclusively in patients with dilated cardiomyopathy etiology. The Arg9 and Leu39 residues are the leading location of mutations described at this locus to date. Despite the few mutated residues described to date, the clinical spectrum of presentation appears to vary considerably. (Source: American Heart Journal)</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5468636</comments>
            <pubDate>Wed, 09 Nov 2011 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">5468636</guid>        </item>
        <item>
            <title>Regional differences in clinical profile, quality of care, and outcomes among Hispanic patients hospitalized with acute myocardial infarction in the Get with Guidelines–Coronary Artery Disease (GWTG-CAD) Registry</title>
            <link>http://www.medworm.com/index.php?rid=5468624&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS0002870311006466%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusions: Among Hispanics with acute MI enrolled in the GWTG-CAD program, there were modest regional differences in clinical profile; high rates of use and, with few exceptions, no regional differences in guideline-recommended therapies; and no regional variation in in-hospital mortality. (Source: American Heart Journal)</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5468624</comments>
            <pubDate>Wed, 09 Nov 2011 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">5468624</guid>        </item>
        <item>
            <title>Rationale and design of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist Trial: A randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction</title>
            <link>http://www.medworm.com/index.php?rid=5468621&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS0002870311006880%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusion: TOPCAT is designed to assess definitively the role of spironolactone in the management of HF-PEF. (Source: American Heart Journal)</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5468621</comments>
            <pubDate>Wed, 09 Nov 2011 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">5468621</guid>        </item>
        <item>
            <title>Effect of oral l-arginine supplementation on blood pressure: A meta-analysis of randomized, double-blind, placebo-controlled trials</title>
            <link>http://www.medworm.com/index.php?rid=5468620&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS0002870311006971%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusions: This meta-analysis provides further evidence that oral l-arginine supplementation significantly lowers both systolic and diastolic BP. (Source: American Heart Journal)</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5468620</comments>
            <pubDate>Wed, 09 Nov 2011 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">5468620</guid>        </item>
        <item>
            <title>Information for Readers</title>
            <link>http://www.medworm.com/index.php?rid=5407604&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS0002870311007290%2Fabstract%3Frss%3Dyes</link>
            <description>(Source: American Heart Journal)</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5407604</comments>
            <pubDate>Tue, 01 Nov 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5407604</guid>        </item>
        <item>
            <title>Editorial Board</title>
            <link>http://www.medworm.com/index.php?rid=5407603&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS0002870311007289%2Fabstract%3Frss%3Dyes</link>
            <description>(Source: American Heart Journal)</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5407603</comments>
            <pubDate>Tue, 01 Nov 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5407603</guid>        </item>
        <item>
            <title>Table of Contents</title>
            <link>http://www.medworm.com/index.php?rid=5407602&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS0002870311007277%2Fabstract%3Frss%3Dyes</link>
            <description>(Source: American Heart Journal)</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5407602</comments>
            <pubDate>Tue, 01 Nov 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5407602</guid>        </item>
        <item>
            <title>Effect of controlled reduction of body iron stores on clinical outcomes in peripheral arterial disease</title>
            <link>http://www.medworm.com/index.php?rid=5407600&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS0002870311006302%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusions: Lower iron burden predicted improved outcomes overall and was enhanced by phlebotomy. Controlling iron burden may improve survival and prevent or delay nonfatal myocardial infarction and stroke. (Source: American Heart Journal)</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5407600</comments>
            <pubDate>Tue, 01 Nov 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5407600</guid>        </item>
        <item>
            <title>Mode of death after contemporary percutaneous coronary intervention: A report from the Evaluation of Drug Eluting Stents and Ischemic Events registry</title>
            <link>http://www.medworm.com/index.php?rid=5407596&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS0002870311006314%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusions: Among unselected PCI patients, 1-year mortality is approximately 3%, and CVD is confirmed in (Source: American Heart Journal)</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5407596</comments>
            <pubDate>Tue, 01 Nov 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5407596</guid>        </item>
        <item>
            <title>Myeloperoxidase in the diagnosis of acute coronary syndromes: The importance of spectrum</title>
            <link>http://www.medworm.com/index.php?rid=5407593&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS0002870311006351%2Fabstract%3Frss%3Dyes</link>
            <description>Background: Myeloperoxidase (MPO) is proposed for risk stratification in patients with suspected acute coronary syndromes (ACSs). We determined if MPO has diagnostic value in patients being evaluated for ACS.Method: MIDAS was an 18-center prospective study enrolling suspected ACS emergency department patients who presented (Source: American Heart Journal)</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5407593</comments>
            <pubDate>Tue, 01 Nov 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5407593</guid>        </item>
        <item>
            <title>Safety and efficacy of adjusted-dose eptifibatide in patients with acute coronary syndromes and reduced renal function</title>
            <link>http://www.medworm.com/index.php?rid=5407592&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS0002870311006399%2Fabstract%3Frss%3Dyes</link>
            <description>We examined the influence of dose modification on bleeding and efficacy.Methods: Based on initial study drug infusion rate, Early GP IIb/IIIa Inhibition in non–ST-segment elevation acute coronary syndromes (EARLY ACS) patients were categorized into groups: standard dose (2 μg/kg/min; estimated creatinine clearance [eCrCl] ≥50 ml/min), adjusted dose (1 μg/kg/min; eCrCl (Source: American Heart Journal)</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5407592</comments>
            <pubDate>Tue, 01 Nov 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5407592</guid>        </item>
        <item>
            <title>Effect of esomeprazole versus famotidine on platelet inhibition by clopidogrel: A double-blind, randomized trial</title>
            <link>http://www.medworm.com/index.php?rid=5407590&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS0002870311006235%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusions: The platelet inhibitory effect of clopidogrel was not significantly different between patients receiving esomeprazole and those receiving famotidine. Neither esomeprazole nor famotidine reduced the platelet inhibitory effect of clopidogrel. (Clinicaltrial.gov Identifier NCT01062516). (Source: American Heart Journal)</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5407590</comments>
            <pubDate>Tue, 01 Nov 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5407590</guid>        </item>
        <item>
            <title>Cognitive impairment and outcomes in older adult survivors of acute myocardial infarction: Findings from the Translational Research Investigating Underlying disparities in acute Myocardial infarction Patients' Health Status registry</title>
            <link>http://www.medworm.com/index.php?rid=5407589&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS000287031100620X%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusions: Most older patients surviving AMI have measurable CIND. Cognitive impairment without dementia was associated with less invasive care, less referral and participation in cardiac rehabilitation, and worse risk-adjusted 1-year survival in those with moderate/severe CIND, making it an important condition to consider in optimizing AMI care. (Source: American Heart Journal)</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5407589</comments>
            <pubDate>Tue, 01 Nov 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5407589</guid>        </item>
        <item>
            <title>Management of acute coronary syndromes in developing countries: ACute Coronary Events—a multinational Survey of current management Strategies</title>
            <link>http://www.medworm.com/index.php?rid=5407588&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS0002870311006259%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusions: In this observational study of patients with ACS, the use of evidence-based pharmacologic therapies for ACS was quite high, yet 39% of eligible patients with STEMI received no reperfusion therapy. These findings suggest opportunities to further reduce the risk of long-term ischemic events in patients with ACS in developing countries. (Source: American Heart Journal)</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5407588</comments>
            <pubDate>Tue, 01 Nov 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5407588</guid>        </item>
        <item>
            <title>Treatment with Adenosine Diphosphate Receptor Inhibitors—Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS) study design: Expanding the paradigm of longitudinal observational research</title>
            <link>http://www.medworm.com/index.php?rid=5407587&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS0002870311006405%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusion: TRANSLATE-ACS not only addresses important clinical and scientific questions but also includes pioneering design features that will assist in the evolution of clinical registries. (Source: American Heart Journal)</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5407587</comments>
            <pubDate>Tue, 01 Nov 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5407587</guid>        </item>
        <item>
            <title>The first call from Dad</title>
            <link>http://www.medworm.com/index.php?rid=5407585&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS0002870311007198%2Fabstract%3Frss%3Dyes</link>
            <description>came in the summer of 2010. He was frustrated that he was on so many medicines and saw so many physicians. I asked him to send me his list of meds to see if there was any way to reduce the list. (Source: American Heart Journal)</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5407585</comments>
            <pubDate>Tue, 01 Nov 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5407585</guid>        </item>
        <item>
            <title>Rationale and design of the MASS COMM trial: A randomized trial to compare percutaneous coronary intervention between MASSachusetts hospitals with cardiac surgery on-site and COMMunity hospitals without cardiac surgery on-site</title>
            <link>http://www.medworm.com/index.php?rid=5407584&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS0002870311006375%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusions: This multicenter, randomized trial will compare the relative safety and effectiveness of nonemergency PCI at sites with and without cardiac SOS. (Source: American Heart Journal)</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5407584</comments>
            <pubDate>Tue, 01 Nov 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5407584</guid>        </item>
        <item>
            <title>The design and rationale of the Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus–Thrombolysis in Myocardial Infarction (SAVOR-TIMI) 53 Study</title>
            <link>http://www.medworm.com/index.php?rid=5407583&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS0002870311006223%2Fabstract%3Frss%3Dyes</link>
            <description>Objectives: Saxagliptin, a dipeptidyl peptidase 4 inhibitor, improves glycemic control in patients with type 2 diabetes mellitus (T2DM) by increasing endogenous active, intact glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide in response to food, which augments insulin secretion and decreases glucagon release.Research Design and Methods: SAVOR-TIMI 53 is a phase 4, randomized, double-blind, placebo-controlled trial conducted in 25 countries that is designed to evaluate the safety and efficacy of saxagliptin during long-term treatment of approximately 16,500 patients with T2DM. Eligible patients who are either treatment naive or on any background antidiabetic treatment (except incretin therapy) with history of established cardiovascular (CV) disease or multiple risk f...</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5407583</comments>
            <pubDate>Tue, 01 Nov 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5407583</guid>        </item>
        <item>
            <title>The Fixed-dose Combination Drug for Secondary Cardiovascular Prevention project: Improving equitable access and adherence to secondary cardiovascular prevention with a fixed-dose combination drug. Study design and objectives</title>
            <link>http://www.medworm.com/index.php?rid=5407582&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS0002870311006296%2Fabstract%3Frss%3Dyes</link>
            <description>In spite of advances in prevention and treatment, the burden of cardiovascular diseases is increasing. A fixed-dose combination (FDC) pill, or “polypill,” composed of evidence-based drugs has been proposed as a means of improving cardiovascular prevention by reducing cost and increasing patient adherence to treatment.The aim of the FOCUS project, funded by the 7th Framework Programme of the European Commission, is to characterize the factors that underlie inadequate secondary prevention and to test a new FDC. To achieve these goals, a 9-member consortium has been constituted, including institutions from Argentina, France, Italy, Spain, and Switzerland.FOCUS Phase-1 will examine factors potentially related to lack of adequate secondary prevention in 4,000 post–myocardial infarction (M...</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5407582</comments>
            <pubDate>Tue, 01 Nov 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5407582</guid>        </item>
        <item>
            <title>LV twisting and untwisting in HCM: Ejection begets filling: Diastolic functional aspects of HCM</title>
            <link>http://www.medworm.com/index.php?rid=5407581&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS0002870311006387%2Fabstract%3Frss%3Dyes</link>
            <description>Conventional and emerging concepts on mechanisms by which hypertrophic cardiomyopathy (HCM) engenders diastolic dysfunction are surveyed. A shift from familiar left ventricular (LV) diastolic function approaches to large-scale (twist-untwist) and small-scale (titin unfolding-refolding, etc.) wall rebound models, incorporating interaction and dynamic distortions and rearrangements of myofiber sheets and ultrastructural constituents, is suggested. Such an emerging new paradigm of diastolic dynamics, emphasizing the relationship of myofiber sheet and ultraconstituent distortion to LV mechanics and end-systolic shape, might clarify intricate patterns of early diastolic rebound and suction, needed for LV filling in many of the polymorphic phenotypes of HCM. (Source: American Heart Journal)</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5407581</comments>
            <pubDate>Tue, 01 Nov 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5407581</guid>        </item>
        <item>
            <title>Heart failure and diabetes: Time to pay attention</title>
            <link>http://www.medworm.com/index.php?rid=5407580&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS0002870311006338%2Fabstract%3Frss%3Dyes</link>
            <description>The development of heart failure (HF) represents an important cardiovascular (CV) complication of diabetes mellitus. Multiple studies have demonstrated that diabetes is associated with increased risk for the development of HF. The mechanisms contributing to this increased HF risk are not well understood but include the frequently associated comorbid conditions of coronary artery disease, hypertension, obesity, renal dysfunction, and increased arterial stiffness. In addition to these risk factors, other mechanisms such as disturbances in cardiac metabolism, abnormal intracellular signaling and calcium handling, increased myocardial fibrosis, local activation of the renin angiotensin system, and direct and indirect effects of advanced glycation end products may also contribute to cardiac dys...</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5407580</comments>
            <pubDate>Tue, 01 Nov 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5407580</guid>        </item>
        <item>
            <title>Relationship between angiographic dynamic and densitometric assessment of myocardial reperfusion and survival in patients with acute myocardial infarction treated with primary percutaneous coronary intervention: The Harmonizing Outcomes with Revascularization and Stents in AMI (HORIZONS-AMI) trial</title>
            <link>http://www.medworm.com/index.php?rid=5468631&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS0002870311006892%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusions: Angiographic TMP can be assessed reliably using either Dyn or Den methods and is a powerful, independent predictor of early and late mortality after primary percutaneous coronary intervention in STEMI. (Source: American Heart Journal)</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5468631</comments>
            <pubDate>Fri, 28 Oct 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5468631</guid>        </item>
        <item>
            <title>Survival after Acute Myocardial Infarction (SAMI) study: The design and implementation of a positive deviance study</title>
            <link>http://www.medworm.com/index.php?rid=5468623&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS0002870311006442%2Fabstract%3Frss%3Dyes</link>
            <description>We present the SAMI study, a national positive deviance study to discover hospital strategies associated with lower 30-day hospital risk–standardized mortality rates (RSMRs). There is marked variation across hospitals in 30-day hospital RSMRs for patients with acute myocardial infarction and little information about what accounts for differences in performance. We first conducted a qualitative study of hospitals in the United States (n = 11; 158 key staff) that ranked in the top 5% of RSMRs for each of the 2 most recent years of data (2005-2006 and 2006-2007) from the Centers for Medicare &amp; Medicaid Services at the time of sample selection and in the bottom 5% for contrast, with diversity among hospitals in key characteristics. Using hypotheses generated in this qualitative stage, we con...</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5468623</comments>
            <pubDate>Wed, 26 Oct 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5468623</guid>        </item>
        <item>
            <title>Intensive glycemic control has no impact on the risk of heart failure in type 2 diabetic patients: Evidence from a 37,229 patient meta-analysis</title>
            <link>http://www.medworm.com/index.php?rid=5407599&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS000287031100634X%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusions: More intensive glycemic control in patients with type 2 diabetes mellitus did not reduce the occurrence of HF events. Furthermore, intensive glycemic control with thiazolidinediones increased the risk of HF. These findings question a direct mechanistic link between hyperglycemia and HF. (Source: American Heart Journal)</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5407599</comments>
            <pubDate>Mon, 10 Oct 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5407599</guid>        </item>
        <item>
            <title>Trends in the use of diagnostic coronary angiography, percutaneous coronary intervention, and coronary artery bypass graft surgery across North Carolina</title>
            <link>http://www.medworm.com/index.php?rid=5407598&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS0002870311006326%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusions: Although the use of all invasive cardiac procedures declined, the relative rate of PCI to Cath increased over the study period. There was also significant variation in the mode of revascularization (CABG and PCI) across hospital systems in North Carolina. Further research is needed to understand drivers of coronary revascularization. (Source: American Heart Journal)</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5407598</comments>
            <pubDate>Mon, 10 Oct 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5407598</guid>        </item>
        <item>
            <title>Long-term tissue coverage of a biodegradable polylactide polymer–coated biolimus-eluting stent: Comparative sequential assessment with optical coherence tomography until complete resorption of the polymer</title>
            <link>http://www.medworm.com/index.php?rid=5407597&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS0002870311006454%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusions: More complete strut coverage of BES as compared with SES at 9 months was followed by improvement of coverage in SES between 9 and 24 months and a similar long-term coverage in both stent types at 24 months. (Source: American Heart Journal)</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5407597</comments>
            <pubDate>Mon, 10 Oct 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5407597</guid>        </item>
        <item>
            <title>Days alive and out of hospital and the patient journey in patients with heart failure: Insights from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program</title>
            <link>http://www.medworm.com/index.php?rid=5407594&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS0002870311005746%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusions: Days alive and out of hospital, especially percent DAOH, provide a valuable tool for summarizing the overall absolute treatment effect on mortality and morbidity. In future HF trials, percent DAOH can provide a useful alternative perspective on the effects of treatment. (Source: American Heart Journal)</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5407594</comments>
            <pubDate>Mon, 10 Oct 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5407594</guid>        </item>
        <item>
            <title>Predicting long-term mortality in older patients after non–ST-segment elevation myocardial infarction: The CRUSADE long-term mortality model and risk score</title>
            <link>http://www.medworm.com/index.php?rid=5407591&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS0002870311006272%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusions: Older patients face substantial long-term mortality risks after NSTEMI that can be accurately predicted from baseline characteristics. These prognostic estimates may support informed treatment decision-making and comparison of long-term provider outcomes. (Source: American Heart Journal)</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5407591</comments>
            <pubDate>Wed, 05 Oct 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5407591</guid>        </item>
        <item>
            <title>Information for Readers</title>
            <link>http://www.medworm.com/index.php?rid=5296857&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS000287031100651X%2Fabstract%3Frss%3Dyes</link>
            <description>(Source: American Heart Journal)</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5296857</comments>
            <pubDate>Sat, 01 Oct 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5296857</guid>        </item>
        <item>
            <title>Editorial Board</title>
            <link>http://www.medworm.com/index.php?rid=5296856&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS0002870311006508%2Fabstract%3Frss%3Dyes</link>
            <description>(Source: American Heart Journal)</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5296856</comments>
            <pubDate>Sat, 01 Oct 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5296856</guid>        </item>
        <item>
            <title>Table of Contents</title>
            <link>http://www.medworm.com/index.php?rid=5296855&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS0002870311006491%2Fabstract%3Frss%3Dyes</link>
            <description>(Source: American Heart Journal)</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5296855</comments>
            <pubDate>Sat, 01 Oct 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5296855</guid>        </item>
        <item>
            <title>Reply to Pizzi et al regarding “Depressive symptoms are related to progression of coronary calcium in midlife women: The Study of Women's Health Across the Nation (SWAN) Heart Study”</title>
            <link>http://www.medworm.com/index.php?rid=5296854&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS0002870311005643%2Fabstract%3Frss%3Dyes</link>
            <description>We appreciate the interest in our article and the comment of Pizzi et al highlighting that some types of antidepressants may have harmful effects in patients with coronary heart disease. The participants in the SWAN as well as in the substudy SWAN Heart were middle-aged women undergoing the menopausal transition. Because rates of cardiovascular disease (CVD) increase for women in this age group, it is important to find ways to reduce their CVD burden. In this healthy population, we found that depressive symptoms were significantly positively related to progression of coronary artery calcification (CAC), an early marker of CVD, especially heart disease. In a recent review article, statins have been shown to be not effective in lowering CAC scores; therefore, it seems prudent to look for oth...</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5296854</comments>
            <pubDate>Sat, 01 Oct 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5296854</guid>        </item>
        <item>
            <title>Cognitive decline and ischemic microlesions after coronary catheterization. A comparison to coronary artery bypass grafting</title>
            <link>http://www.medworm.com/index.php?rid=5296846&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS0002870311005631%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusions: As compared with CABG, PICD and cerebral lesions appear to be substantially milder after coronary catheter intervention, but not negligible. (Source: American Heart Journal)</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5296846</comments>
            <pubDate>Sat, 01 Oct 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5296846</guid>        </item>
        <item>
            <title>Predictors of fatal and nonfatal cardiovascular events in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia: An analysis of the Trial to Reduce cardiovascular Events with Aranesp (darbepoetin-alfa) Therapy (TREAT)</title>
            <link>http://www.medworm.com/index.php?rid=5296845&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS0002870311005588%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusion: In patients with diabetes, CKD, and anemia, cardiovascular risk is most strongly predicted by age, history of HF, C-reactive protein, urinary protein/creatinine ratio, abnormal electrocardiogram, and 2 specific cardiac biomarkers, serum N-terminal pro B-type natriuretic peptide and troponin T, which are elevated in many. These findings suggest ways to improve cardiovascular risk stratification of patients with predialysis CKD, support the concept of cardiorenal syndrome, and may help target therapy. (Source: American Heart Journal)</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5296845</comments>
            <pubDate>Sat, 01 Oct 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5296845</guid>        </item>
        <item>
            <title>A meta-analysis of specifically designed randomized trials of sirolimus-eluting versus paclitaxel-eluting stents in diabetic patients with coronary artery disease</title>
            <link>http://www.medworm.com/index.php?rid=5296844&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS0002870311004984%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusions: In diabetic patients with coronary artery disease, SES leads to a sustained reduction in the risk of TLR compared with PES. Both these DES types are, however, comparable with respect to the risk of stent thrombosis, MI, or death over long-term follow-up. (Source: American Heart Journal)</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5296844</comments>
            <pubDate>Sat, 01 Oct 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5296844</guid>        </item>
        <item>
            <title>Cluster-randomized trial to evaluate the effects of a quality improvement program on management of non–ST-elevation acute coronary syndromes: The European Quality Improvement Programme for Acute Coronary Syndromes (EQUIP-ACS)</title>
            <link>http://www.medworm.com/index.php?rid=5296839&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS0002870311005710%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusions: The QI strategy resulted in a significant improvement in the quality indicators measured. This type of QI intervention can lead to useful changes in health care practice for ACS in a wide range of settings. (Source: American Heart Journal)</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5296839</comments>
            <pubDate>Sat, 01 Oct 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5296839</guid>        </item>
        <item>
            <title>Is the measurement of left ventricular ejection fraction the proper end point for cell therapy trials? An analysis of the effect of bone marrow mononuclear stem cell administration on left ventricular ejection fraction after ST-segment elevation myocardial infarction when evaluated by cardiac magnetic resonance imaging</title>
            <link>http://www.medworm.com/index.php?rid=5296835&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS0002870311004893%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusions: The benefit of BMC administration after STEMI on LVEF, LV volumes, and infarct size is small when assessed by cMRI. (Source: American Heart Journal)</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5296835</comments>
            <pubDate>Sat, 01 Oct 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5296835</guid>        </item>
        <item>
            <title>Incidence and predictors of heart failure following percutaneous coronary intervention in ST-segment elevation myocardial infarction: The HORIZONS-AMI trial</title>
            <link>http://www.medworm.com/index.php?rid=5296834&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS0002870311005734%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusion: In the HORIZONS-AMI trial, the development of new-onset CHF within 2 years after contemporary PCI, although infrequent, was associated with significantly increased rates of mortality and major adverse ischemic events. (Source: American Heart Journal)</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5296834</comments>
            <pubDate>Sat, 01 Oct 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5296834</guid>        </item>
        <item>
            <title>The National Registry of Genetically Triggered Thoracic Aortic Aneurysms and Cardiovascular Conditions (GenTAC): Results from phase I and scientific opportunities in phase II</title>
            <link>http://www.medworm.com/index.php?rid=5296829&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS0002870311004972%2Fabstract%3Frss%3Dyes</link>
            <description>Background: Genetically triggered thoracic aortic conditions (GenTACs) represent an important problem for patients and their families. Accordingly, the National Heart, Lung, and Blood Institute established the first phase of its national GenTAC Registry in 2006.Enrollment and Diagnoses: Between 2007 and 2010, 6 enrolling centers established the GenTAC I Registry consisting of 2,046 patients (Marfan syndrome 576 [28.2%], bicuspid aortic valve disease 504 [24.6%], aneurysm or dissection age (Source: American Heart Journal)</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5296829</comments>
            <pubDate>Sat, 01 Oct 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5296829</guid>        </item>
        <item>
            <title>Outcomes registry for better informed treatment of atrial fibrillation: Rationale and design of ORBIT-AF</title>
            <link>http://www.medworm.com/index.php?rid=5296826&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS0002870311004960%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusion: The Outcomes Registry for Better Informed Treatment of Atrial Fibrillation will provide insights into “real-world” treatment including rate and rhythm control, stroke prevention, transitions to new therapies, and clinical and patient-centered outcomes among patients with AF in community practice settings (ClinicalTrials.gov NCT01165710). (Source: American Heart Journal)</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5296826</comments>
            <pubDate>Sat, 01 Oct 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5296826</guid>        </item>
        <item>
            <title>Long-term clinical outcome in patients with small vessel disease treated with drug-eluting versus bare-metal stenting</title>
            <link>http://www.medworm.com/index.php?rid=5407595&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS0002870311005667%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusions: In small vessel disease, DES was more frequently implanted in pts at higher risk of restenosis, though it demonstrated to be more effective than BMS in reducing MACE and TVR at long-term follow-up. (Source: American Heart Journal)</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5407595</comments>
            <pubDate>Mon, 26 Sep 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5407595</guid>        </item>
        <item>
            <title>Should all patients be treated with an angiotensin-converting enzyme inhibitor after coronary artery bypass graft surgery? The impact of angiotensin-converting enzyme inhibitors, statins, and β-blockers after coronary artery bypass graft surgery</title>
            <link>http://www.medworm.com/index.php?rid=5407586&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS0002870311004996%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusions: Among patients after CABG 65 years or older, ACE inhibitors had no independent effect on mortality or recurrent ischemic events in the midterm after CABG, although a benefit was observed for statins and β-blockers. (Source: American Heart Journal)</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5407586</comments>
            <pubDate>Mon, 26 Sep 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5407586</guid>        </item>
        <item>
            <title>Delayed arterial healing 5 years after implantation of sirolimus-eluting stents: No smoke without fire</title>
            <link>http://www.medworm.com/index.php?rid=5407601&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS0002870311006247%2Fabstract%3Frss%3Dyes</link>
            <description>With great interest, we read the article “The possibility of delayed arterial healing 5 years after implantation of sirolimus-eluting stents: Serial observations by coronary angioscopy” by Yamamoto et al. Their landmark observation by coronary angioscopy was the persistence of “uncovered” stent struts in almost 30% of patients 5 years after implantation of sirolimus-eluting stents. Moreover, they demonstrated subclinical thrombi in 35% of patients both at 2- and 5-year follow-up; most of them were most likely “fresh” ones. (Source: American Heart Journal)</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5407601</comments>
            <pubDate>Tue, 20 Sep 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5407601</guid>        </item>
        <item>
            <title>Improvement in use of anticoagulation therapy in patients with ischemic stroke: Results from Get With The Guidelines–Stroke</title>
            <link>http://www.medworm.com/index.php?rid=5296838&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS0002870311005618%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusions: Use of anticoagulation among stroke patients with AF has increased to very high levels overall in GWTG-Stroke over time. Future efforts should focus on improving use among selected populations. (Source: American Heart Journal)</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5296838</comments>
            <pubDate>Mon, 19 Sep 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5296838</guid>        </item>
        <item>
            <title>Prognostic value of serial measurements of highly sensitive cardiac troponin I in stable outpatients with nonischemic chronic heart failure</title>
            <link>http://www.medworm.com/index.php?rid=5296831&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS0002870311005023%2Fabstract%3Frss%3Dyes</link>
            <description>Background: Cardiac troponin I (cTnI) is a useful biomarker in patients with chronic heart failure (CHF), and a highly sensitive cTnI (hs-cTnI) commercial assay has become available. However, the prognostic role of serial measurements of hs-cTnI in stable outpatients with CHF remains unknown.Methods: At entry to the study, we evaluated 95 stable outpatients with nonischemic CHF showing a serum hs-cTnI (Centaur TnI-Ultra [Siemens Medical Solution Diagnostics, New York, NY], lower limit of detection 0.006 ng/mL) value ≥0.006 ng/mL. To evaluate the role of repetitive measurements of hs-cTnI, we performed echocardiography and measured serum levels of cTnI and N-terminal proBNP at baseline and 6 months later and then prospectively followed up these patients for 4.25 years.Results: During long...</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5296831</comments>
            <pubDate>Mon, 19 Sep 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5296831</guid>        </item>
        <item>
            <title>Study design and rationale for the Stabilization of pLaques usIng Darapladib—Thrombolysis in Myocardial Infarction (SOLID-TIMI 52) trial in patients after an acute coronary syndrome</title>
            <link>http://www.medworm.com/index.php?rid=5296827&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS0002870311005606%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusions: The SOLID-TIMI 52 trial will determine the clinical benefit of direct inhibition of Lp-PLA2 activity with darapladib in patients after an acute coronary syndrome. (Source: American Heart Journal)</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5296827</comments>
            <pubDate>Mon, 19 Sep 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5296827</guid>        </item>
        <item>
            <title>Effect of informed consent format on patient anxiety, knowledge, and satisfaction</title>
            <link>http://www.medworm.com/index.php?rid=5296849&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS0002870311005011%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusion: For electrophysiologic testing, all 3 formats have similar effects on anxiety and produce equivalent patient comprehension. The oral format requires more physician time. Given the standardization achievable with a written or video format, physicians may consider these options to facilitate obtaining informed consent. (Source: American Heart Journal)</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5296849</comments>
            <pubDate>Fri, 16 Sep 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5296849</guid>        </item>
        <item>
            <title>Adherence to the Mediterranean diet in relation to acute coronary syndrome or stroke nonfatal events: A comparative analysis of a case/case-control study</title>
            <link>http://www.medworm.com/index.php?rid=5296841&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS0002870311005540%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusions: The present work extended the current knowledge about the cardioprotective benefits from the adoption of the Mediterranean diet by showing an additional protective effect on ischemic stroke development. (Source: American Heart Journal)</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5296841</comments>
            <pubDate>Fri, 16 Sep 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5296841</guid>        </item>
        <item>
            <title>Cardiac structure and function, remodeling, and clinical outcomes among patients with diabetes after myocardial infarction complicated by left ventricular systolic dysfunction, heart failure, or both</title>
            <link>http://www.medworm.com/index.php?rid=5296837&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS0002870311005576%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusions: After high-risk MI, diabetic patients were at higher risk of death or HF and demonstrated greater baseline LV mass index, relative wall thickness, and LAVi as well as greater left atrial enlargement at 20-month follow-up. These findings suggest greater baseline concentric remodeling and long-term elevation in LV diastolic pressure post-MI among diabetic patients, which may partially mediate this risk. (Source: American Heart Journal)</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5296837</comments>
            <pubDate>Fri, 16 Sep 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5296837</guid>        </item>
        <item>
            <title>The impact of left ventricular size on response to cardiac resynchronization therapy</title>
            <link>http://www.medworm.com/index.php?rid=5296832&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS0002870311005035%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusion: Patients with NDCM and SDCM experience significant improvements in LVEF after CRT. The degree of baseline left ventricular dilatation before CRT is an important predictor of subsequent changes in LVEF and survival. (Source: American Heart Journal)</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5296832</comments>
            <pubDate>Fri, 16 Sep 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5296832</guid>        </item>
        <item>
            <title>Prospective study of infective endocarditis from a developing country</title>
            <link>http://www.medworm.com/index.php?rid=5296830&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS0002870311005564%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusion: The mean age of IE in India is significantly lower than that in the West. Unlike previous reports, congenital heart disease is the major predisposing factor. Culture positivity rates and surgery for IE are unacceptably low. In conclusion, IE in India is associated with a very high morbidity and mortality. (Source: American Heart Journal)</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5296830</comments>
            <pubDate>Fri, 16 Sep 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5296830</guid>        </item>
        <item>
            <title>EXamination of CArdiovascular OutcoMes with AlogliptIN versus Standard of CarE in Patients with Type 2 Diabetes Mellitus and Acute Coronary Syndrome (EXAMINE) A cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes with acute coronary syndrome</title>
            <link>http://www.medworm.com/index.php?rid=5296828&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS0002870311005758%2Fabstract%3Frss%3Dyes</link>
            <description>Comprehensive safety evaluation of new drugs for diabetes mellitus is needed in the area of cardiovascular (CV) outcomes, particularly in populations with high CV risk. Alogliptin, a dipeptidyl peptidase 4 inhibitor, is under development for the treatment of type 2 diabetes mellitus alone or in combination with other antidiabetic therapies. Long-term CV safety of alogliptin is being established in a randomized, placebo-controlled clinical study in patients with acute coronary syndrome (ACS) using an analytical approach that has both an interim and final assessment. The primary CV end point for this trial is a composite of CV death, nonfatal myocardial infarction, and nonfatal stroke. Approximately 5,400 men and women with type 2 diabetes and ACS (acute myocardial infarction or unstable ang...</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5296828</comments>
            <pubDate>Fri, 16 Sep 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5296828</guid>        </item>
        <item>
            <title>Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: Rationale and Design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS)</title>
            <link>http://www.medworm.com/index.php?rid=5296825&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS0002870311004820%2Fabstract%3Frss%3Dyes</link>
            <description>Background: Inflammation contributes to all phases of the atherothrombotic process, and patients with elevated inflammatory biomarkers such as high-sensitivity C-reactive protein (hsCRP) have increased vascular risk. Yet, it remains unknown whether direct inhibition of inflammation will reduce cardiovascular event rates.Design: The CANTOS will evaluate whether interleukin-1β (IL-1β) inhibition as compared with placebo can reduce rates of recurrent myocardial infarction, stroke, and cardiovascular death among stable patients with coronary artery disease who remain at high vascular risk due to persistent elevations of hsCRP (&gt;2 mg/L) despite contemporary secondary prevention strategies. Canakinumab is a human monoclonal antibody that selectively neutralizes IL-1β, a proinflammatory cytoki...</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5296825</comments>
            <pubDate>Fri, 16 Sep 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5296825</guid>        </item>
        <item>
            <title>Training providers in hypertension guidelines: Cost-effectiveness evaluation of a continuing medical education program in South Carolina</title>
            <link>http://www.medworm.com/index.php?rid=5296850&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS0002870311004923%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusions: The intervention is likely a cost-effective strategy to address hypertension in a real-world setting and can serve as a model for future innovations in hypertension prevention. (Source: American Heart Journal)</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5296850</comments>
            <pubDate>Mon, 12 Sep 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5296850</guid>        </item>
        <item>
            <title>Downstream coronary effects of drug-eluting stents</title>
            <link>http://www.medworm.com/index.php?rid=5296847&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS0002870311005722%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusions: Patients receiving DES appear less likely to develop downstream stenoses and events compared with patients receiving bare-metal stents, suggesting beneficial downstream drug delivery. (Source: American Heart Journal)</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5296847</comments>
            <pubDate>Mon, 12 Sep 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5296847</guid>        </item>
        <item>
            <title>A double-blind, randomized, controlled, multicenter study to assess the safety and cardiovascular effects of skeletal myoblast implantation by catheter delivery in patients with chronic heart failure after myocardial infarction</title>
            <link>http://www.medworm.com/index.php?rid=5296833&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS000287031100562X%2Fabstract%3Frss%3Dyes</link>
            <description>Background: We sought to determine the safety and preliminary efficacy of transcatheter intramyocardial administration of myoblasts in patients with heart failure (HF).Methods: MARVEL is a randomized placebo-controlled trial of image-guided, catheter-based intramyocardial injection of placebo or myoblasts (400 or 800 million) in patients with class II to IV HF and ejection fraction (Source: American Heart Journal)</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5296833</comments>
            <pubDate>Mon, 12 Sep 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5296833</guid>        </item>
        <item>
            <title>Measuring and targeting aldosterone and renin in atherosclerosis—A review of clinical data</title>
            <link>http://www.medworm.com/index.php?rid=5296824&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS0002870311004856%2Fabstract%3Frss%3Dyes</link>
            <description>Our understanding of the development and progression of atherosclerosis has increased substantially over the past decades. A significant role for the renin-angiotensin-aldosterone system (RAAS) in this process has gained appreciation in recent years. Preclinical and clinical studies have associated components of the RAAS with various cardiovascular disease conditions. Classically known for its contribution to hypertension, dysregulation of the system is now also believed to promote vascular inflammation, fibrosis, remodeling, and endothelial dysfunction, all intimately related to atherosclerosis.The reduction in cardiovascular mortality and morbidity, as seen with the use of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers, supports the concept that RAAS is invo...</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5296824</comments>
            <pubDate>Mon, 12 Sep 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5296824</guid>        </item>
        <item>
            <title>In women with symptoms of cardiac ischemia, nonobstructive coronary arteries, and microvascular dysfunction, angiotensin-converting enzyme inhibition is associated with improved microvascular function: A double-blind randomized study from the National Heart, Lung and Blood Institute Women's Ischemia Syndrome Evaluation (WISE)</title>
            <link>http://www.medworm.com/index.php?rid=5296836&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS0002870311005163%2Fabstract%3Frss%3Dyes</link>
            <description>Background: We investigated the role of the renin-angiotensin system in women with signs and symptoms of ischemia without obstructive coronary artery disease (CAD). Although microvascular dysfunction has been suggested to explain this syndrome and recently was found to predict adverse outcomes, the mechanisms and treatments remain unclear.Methods: In a substudy within the WISE, 78 women with microvascular dysfunction (coronary flow reserve [CFR] (Source: American Heart Journal)</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5296836</comments>
            <pubDate>Wed, 07 Sep 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5296836</guid>        </item>
        <item>
            <title>Appropriateness use criteria for transthoracic echocardiography: Relationship with radiology benefit managers preauthorization determination and comparison of the new (2010) criteria to the original (2007) criteria</title>
            <link>http://www.medworm.com/index.php?rid=5296848&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS0002870311005047%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusion: The updated AUC (2010) provide enhanced clinical value compared with 2007 AUC. There is limited agreement between RBM preauthorization determination and 2007 AUC rating. (Source: American Heart Journal)</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5296848</comments>
            <pubDate>Mon, 05 Sep 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5296848</guid>        </item>
        <item>
            <title>Prasugrel overcomes high on-clopidogrel platelet reactivity in chronic coronary artery disease patients more effectively than high dose (150 mg) clopidogrel</title>
            <link>http://www.medworm.com/index.php?rid=5296843&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS0002870311005709%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusions: Prasugrel appears more effective than double clopidogrel in inhibiting PR in patients with HTPR following chronic clopidogrel treatment. (Source: American Heart Journal)</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5296843</comments>
            <pubDate>Mon, 05 Sep 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5296843</guid>        </item>
        <item>
            <title>Efficacy of exercise-based cardiac rehabilitation post–myocardial infarction: A systematic review and meta-analysis of randomized controlled trials</title>
            <link>http://www.medworm.com/index.php?rid=5296823&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS000287031100559X%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusions: Exercise-based CR is associated with reductions in mortality and reinfarction post-MI. Our secondary analyses suggest that even shorter CR programs may translate into improved long-term outcomes, although these results need to be confirmed in an RCT. (Source: American Heart Journal)</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5296823</comments>
            <pubDate>Mon, 05 Sep 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5296823</guid>        </item>
        <item>
            <title>Efficacy and safety after cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib (MK-0859) in patients with primary hypercholesterolemia or mixed hyperlipidemia</title>
            <link>http://www.medworm.com/index.php?rid=5296840&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS0002870311005059%2Fabstract%3Frss%3Dyes</link>
            <description>This report describes the lipid and safety data collected during an off-drug period that followed 8 weeks of treatment with the cholesteryl ester transfer protein inhibitor, anacetrapib (ANA). A total of 589 patients with primary hypercholesterolemia or mixed hyperlipidemia were randomized to placebo, atorvastatin (ATV) 20 mg, and varying doses of ANA, provided as monotherapy or coadministered with ATV 20 mg daily. Patients were treated for 8 weeks, followed by an 8-week follow-up period, during which ANA was switched to placebo. At week 16 (8 weeks after ANA was stopped), persistent reductions in low-density lipoprotein cholesterol (LDL-C) were evident for the monotherapy groups receiving ANA 150 and 300 mg (−9.3% and −15.3%, respectively), and residual increases in high-density lipop...</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5296840</comments>
            <pubDate>Fri, 02 Sep 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5296840</guid>        </item>
        <item>
            <title>Correction</title>
            <link>http://www.medworm.com/index.php?rid=5296851&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS0002870311006260%2Fabstract%3Frss%3Dyes</link>
            <description>The article “Chronic kidney disease and prevalent atrial fibrillation: The Chronic Renal Insufficiency Cohort (CRIC)” (Am Heart J 2010;159:1102-1107) was published with an error in the label of the gender. In the Abstract (Results), Table III, Table IV, and the Results section (page 1104, bottom line of the left-hand panel), “female sex” should have been “male sex.” We apologize for any confusion or inconvenience this has caused. (Source: American Heart Journal)</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5296851</comments>
            <pubDate>Thu, 01 Sep 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5296851</guid>        </item>
        <item>
            <title>Information for Readers</title>
            <link>http://www.medworm.com/index.php?rid=5183732&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS0002870311005801%2Fabstract%3Frss%3Dyes</link>
            <description>(Source: American Heart Journal)</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5183732</comments>
            <pubDate>Wed, 31 Aug 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">5183732</guid>        </item>
        <item>
            <title>Editorial Board</title>
            <link>http://www.medworm.com/index.php?rid=5183731&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS0002870311005795%2Fabstract%3Frss%3Dyes</link>
            <description>(Source: American Heart Journal)</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5183731</comments>
            <pubDate>Wed, 31 Aug 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">5183731</guid>        </item>
        <item>
            <title>Table of Contents</title>
            <link>http://www.medworm.com/index.php?rid=5183730&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS0002870311005783%2Fabstract%3Frss%3Dyes</link>
            <description>(Source: American Heart Journal)</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5183730</comments>
            <pubDate>Wed, 31 Aug 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">5183730</guid>        </item>
        <item>
            <title>Altered health status and quality of life in South Asians with coronary artery disease</title>
            <link>http://www.medworm.com/index.php?rid=5183718&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS0002870311004789%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusion: South Asian Canadians with established CAD have significantly worse health status outcomes at 1 year after angiography compared with European Canadians. Further studies are warranted to improve functional outcomes in SA with CAD. (Source: American Heart Journal)</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5183718</comments>
            <pubDate>Wed, 31 Aug 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">5183718</guid>        </item>
        <item>
            <title>Temporal changes in emergency department triage of patients with acute myocardial infarction and the effect on outcomes</title>
            <link>http://www.medworm.com/index.php?rid=5183711&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS0002870311004029%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusion: Emergency department triage of patients with AMI improved substantially over 5 years. For the third of patients with AMI who continue to receive a low priority score, including 25% of patients with STEMI, the associated delays in diagnosis and therapy were greater than previously and were associated with increased hospital LOS and mortality. Given the impact of this initial, cursory assessment, hospital systems should consider monitoring the quality of their ED triage. (Source: American Heart Journal)</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5183711</comments>
            <pubDate>Wed, 31 Aug 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">5183711</guid>        </item>
        <item>
            <title>Medication adherence: A call for action</title>
            <link>http://www.medworm.com/index.php?rid=5183707&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS0002870311004753%2Fabstract%3Frss%3Dyes</link>
            <description>This article provides results of a recent think-tank meeting in which various stakeholder groups representing key experts from consumers, community health providers, the academic community, decision-making government officials (Food and Drug Administration, National Institutes of Health, etc), and industry scientists met to evaluate the current status of medication adherence and provide recommendations for improving outcomes. Below, we review the magnitude of the problem of medication adherence, prevalence, impact, and cost. We then summarize proven effective approaches and conclude with a discussion of recommendations to address this growing and significant public health issue of medication nonadherence. (Source: American Heart Journal)</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5183707</comments>
            <pubDate>Wed, 31 Aug 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">5183707</guid>        </item>
        <item>
            <title>Frequency and correlates of treatment intensification for elevated cholesterol levels in patients with cardiovascular disease</title>
            <link>http://www.medworm.com/index.php?rid=5296842&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS0002870311005552%2Fabstract%3Frss%3Dyes</link>
            <description>Background: Although current performance measures define low-density-lipoprotein cholesterol (LDL-C) levels (Source: American Heart Journal)</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5296842</comments>
            <pubDate>Fri, 26 Aug 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5296842</guid>        </item>
        <item>
            <title>Regarding “Depressive symptoms are related to progression of coronary calcium in midlife women: The Study of Women's Health Across the Nation (SWAN) Heart Study”</title>
            <link>http://www.medworm.com/index.php?rid=5296853&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS0002870311005655%2Fabstract%3Frss%3Dyes</link>
            <description>Discussion” section, the authors stated that treating depressive disorders may help to prevent subclinical atherosclerosis progression. However, in the study of Janssen et al, women with CAC progression treated for depression have the same risk of atherosclerosis progression as women with depression without CAC progression. In particular, in Table 1, we noted that there were 8 (11.9%) of 67 women with CAC progression versus 26 (9.3%) of 279 with no CAC progression; however, this difference is not statistically significant. Although antidepressants are generally effective in reducing depression, their use in patients with coronary heart disease is controversial. In their study, the authors might have used a different class of antidepressant drug, which might affect the results. Recent dat...</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5296853</comments>
            <pubDate>Mon, 22 Aug 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5296853</guid>        </item>
        <item>
            <title>Pulmonary arterial capacitance in children with idiopathic pulmonary arterial hypertension and pulmonary arterial hypertension associated with congenital heart disease: Relation to pulmonary vascular resistance, exercise capacity, and survival</title>
            <link>http://www.medworm.com/index.php?rid=5183728&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS0002870311004844%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusions: Low PACi and high PVRi are independently associated with low 6-minute walk distance and survival in children with PAH. Therefore, both should be assessed for better prognostication and management in this high-risk population. (Source: American Heart Journal)</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5183728</comments>
            <pubDate>Thu, 11 Aug 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">5183728</guid>        </item>
        <item>
            <title>Clinical significance of late high-degree atrioventricular block in patients with left ventricular dysfunction after an acute myocardial infarction—A Cardiac Arrhythmias and Risk Stratification After Acute Myocardial Infarction (CARISMA) substudy</title>
            <link>http://www.medworm.com/index.php?rid=5183725&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS0002870311004911%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusion: High-degree atrioventricular block documented by continuous ECG monitoring occurring more than 3 weeks after AMI is a frequent complication in post-AMI patients with left ventricular dysfunction. Furthermore, HAVB is associated with ominous prognostic implications of both potentially lethal arrhythmias and heart failure. (Source: American Heart Journal)</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5183725</comments>
            <pubDate>Thu, 11 Aug 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">5183725</guid>        </item>
        <item>
            <title>Vitamin D status is not related to development of atrial fibrillation in the community</title>
            <link>http://www.medworm.com/index.php?rid=5183724&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS0002870311004832%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusion: In our community-based sample, vitamin D status was not related to incident AF. Our data suggest that vitamin D deficiency does not promote the development of AF in the ambulatory setting. (Source: American Heart Journal)</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5183724</comments>
            <pubDate>Thu, 11 Aug 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">5183724</guid>        </item>
        <item>
            <title>Impact of smoking on antiplatelet effect of clopidogrel and prasugrel after loading dose and on maintenance therapy</title>
            <link>http://www.medworm.com/index.php?rid=5183721&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS0002870311004170%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusions: Smoking does not impact on platelet reactivity in patients after loading or on different maintenance doses of clopidogrel. The clinical treatment effect of clopidogrel versus prasugrel is not affected by smoking status at presentation. (Source: American Heart Journal)</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5183721</comments>
            <pubDate>Thu, 11 Aug 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">5183721</guid>        </item>
        <item>
            <title>Effects of verbal suggestion on coronary arteries: Results of a randomized controlled experimental investigation during coronary angiography</title>
            <link>http://www.medworm.com/index.php?rid=5183719&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS0002870311004868%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusion: The findings of this study suggest that a VS results in a biological alteration within coronary arteries. Contrary to expectation, the VS led to vasoconstriction, whereas chest pain perception decreased. (Source: American Heart Journal)</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5183719</comments>
            <pubDate>Thu, 11 Aug 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">5183719</guid>        </item>
        <item>
            <title>Trends in Q-wave acute myocardial infarction case fatality from 1978 to 2007 and analysis of the effectiveness of different treatments</title>
            <link>http://www.medworm.com/index.php?rid=5183710&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS000287031100487X%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusion: A dramatic decrease in 28-day case fatality occurred during this 30-year period and was mainly related to the use of antiplatelet drugs, β-blockers, thrombolysis, and invasive procedures. These data support the current guidelines for the management of acute coronary syndrome. (Source: American Heart Journal)</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5183710</comments>
            <pubDate>Thu, 11 Aug 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">5183710</guid>        </item>
        <item>
            <title>The need for transformative innovation in hypertension management</title>
            <link>http://www.medworm.com/index.php?rid=5183706&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS0002870311004790%2Fabstract%3Frss%3Dyes</link>
            <description>Despite multiple available effective therapies for hypertension, many patients with high blood pressure in the United States are not adequately controlled. This inability to effectively manage hypertension can be attributed to patient, provider, and system failures. To create an effective model for hypertension management, current care delivery systems must be reorganized around the following principles: improved patient engagement and patient-provider communication, increased use of nonphysician providers, better performance monitoring and feedback systems, and better aligned reimbursement models. Transformation of care around these principles would lead to marked improvements in cost, quality, and access to care. (Source: American Heart Journal)</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5183706</comments>
            <pubDate>Thu, 11 Aug 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">5183706</guid>        </item>
        <item>
            <title>Letter to the Editor regarding “Outcomes in patients with chronicity of left bundle-branch block with possible acute myocardial infarction”</title>
            <link>http://www.medworm.com/index.php?rid=5296852&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS000287031100500X%2Fabstract%3Frss%3Dyes</link>
            <description>We very much appreciate the article by Kontos et al, which clearly shows that new left bundle-branch block (LBBB) is a very nonspecific sign of myocardial infarction (MI) as diagnosed by biomarkers. This is in accord with multiple other studies. The data strongly suggest that concordance is quite specific (86%); however, sensitivity was very low. This is to be expected for 2 reasons. First, ST elevation is only about 45% sensitive for MI (ST-segment elevation MI + non–ST-segment elevation MI) even in normal conduction. It is only sensitive for coronary occlusion (ST-segment elevation MI). Second, left anterior descending coronary artery (LAD) occlusion will never result in concordance in leads V1 to V4; it may result in concordance in leads I and aVL if the occlusion is proximal (because...</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5296852</comments>
            <pubDate>Thu, 11 Aug 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5296852</guid>        </item>
        <item>
            <title>Correction</title>
            <link>http://www.medworm.com/index.php?rid=5183729&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS0002870311005679%2Fabstract%3Frss%3Dyes</link>
            <description>The author has noticed an error in Table III in the article “Oral antiplatelet therapy for atherothrombotic disease: Current evidence and new directions” (Am Heart J 2011;161:450-461). The dosing of elinogrel is described as “once daily,” whereas it should be “twice daily.” (Source: American Heart Journal)</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5183729</comments>
            <pubDate>Tue, 09 Aug 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">5183729</guid>        </item>
        <item>
            <title>The CHADS2 score predicts ischemic stroke in the absence of atrial fibrillation among subjects with coronary heart disease: Data from the Heart and Soul Study</title>
            <link>http://www.medworm.com/index.php?rid=5183727&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS0002870311004121%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusions: The CHADS2 score predicts ischemic stroke/TIA in subjects with stable CHD and no baseline AF. The event rate in non-AF subjects with high CHADS2 scores (5-6) was comparable with published rates in AF patients with moderate CHADS2 scores (1-2), a population known to derive benefit from stroke prevention therapies. These findings should inform efforts to determine whether stroke prevention therapies or screening for silent AF may benefit subjects with stable CHD and high CHADS2 scores. (Source: American Heart Journal)</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5183727</comments>
            <pubDate>Tue, 09 Aug 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">5183727</guid>        </item>
        <item>
            <title>Prognostic assessment of estimated glomerular filtration rate by the new Chronic Kidney Disease Epidemiology Collaboration equation in comparison with the Modification of Diet in Renal Disease Study equation</title>
            <link>http://www.medworm.com/index.php?rid=5183726&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS0002870311004741%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusion: The CKD-EPI equation provides more accurate risk stratification than the MDRD Study equation in patients at high risk for CV disease, including identification of increased risk at mildly decreased eGFR. (Source: American Heart Journal)</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5183726</comments>
            <pubDate>Tue, 09 Aug 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">5183726</guid>        </item>
        <item>
            <title>Funding source and author affiliation in TASER research are strongly associated with a conclusion of device safety</title>
            <link>http://www.medworm.com/index.php?rid=5183723&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS0002870311004194%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusions: Studies funded by TASER and/or written by an author affiliated with the company are substantially more likely to conclude that TASERs are safe. Research supported by TASER International may thus be significantly biased in favor of TASER safety. (Source: American Heart Journal)</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5183723</comments>
            <pubDate>Tue, 09 Aug 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">5183723</guid>        </item>
        <item>
            <title>Diabetes, quality of care, and in-hospital outcomes in patients hospitalized with heart failure</title>
            <link>http://www.medworm.com/index.php?rid=5183715&amp;cid=s_33877_7_f&amp;fid=33877&amp;url=http%3A%2F%2Fwww.ahjonline.com%2Farticle%2FPIIS0002870311004777%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusions: With few exceptions, the application of evidence-based care and in-hospital outcomes were similar whether or not diabetes was present in this large contemporary cohort of patients hospitalized with HF. (Source: American Heart Journal)</description>
            <author>American Heart Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5183715</comments>
            <pubDate>Tue, 09 Aug 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">5183715</guid>        </item>
    </channel>
</rss>

